Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025)

Historic FCF Margin for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to 1575.07%.

  • X4 Pharmaceuticals' FCF Margin rose 45020700.0% to 1575.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 293.7%, marking a year-over-year increase of 142041700.0%. This contributed to the annual value of 5047.19% for FY2024, which is N/A changed from last year.
  • Per X4 Pharmaceuticals' latest filing, its FCF Margin stood at 1575.07% for Q3 2025, which was up 45020700.0% from 1515.46% recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' FCF Margin registered a high of 2391.43% during Q1 2023, and its lowest value of 11961.1% during Q2 2024.
  • For the 4-year period, X4 Pharmaceuticals' FCF Margin averaged around 1181.41%, with its median value being 43.05% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 1733600bps in 2023, then surged by 104456400bps in 2025.
  • Over the past 4 years, X4 Pharmaceuticals' FCF Margin (Quarter) stood at 1671.94% in 2022, then surged by 43bps to 2391.43% in 2023, then crashed by -184bps to 2019.03% in 2024, then grew by 22bps to 1575.07% in 2025.
  • Its FCF Margin was 1575.07% in Q3 2025, compared to 1515.46% in Q2 2025 and 43.05% in Q1 2025.